

EXHIBIT B

Form PTO-1449		U.S. Department of Commerce Patent and Trademark Office		Atty. Docket No. 60772-PCT-US		U.S. Serial No. 09/768,872				
INFORMATION DISCLOSURE CITATION (Use several sheets if necessary)				Applicant: Rina Aharoni et al.		Group Art Unit				
				Filing Date: January 23, 2001						
U.S. PATENT DOCUMENTS										
Examiner Initial		Document Number				Date	Name	Class	Subclass	Filing Date if Appropriate
		1 3 9 9 1 2 1 0				11/9/76	Shea			
		2 4 1 2 9 6 6 6				12/12/78	Wizerkaniuk			
		3 4 5 9 4 4 0 9				11/19/74	Hayashi et al.			
		4 5 9 6 5 6 0 0				10/12/99	Sato, et al.			
		5 6 0 2 4 9 8 1				2/15/00	Khankari, et al.			
		6 6 1 6 2 8 0 0				12/19/00	Dolle, et al.			
		7 6 3 6 2 1 6 1				3/26/02	Kontino, et al.			
		8 6 5 1 4 9 3 8				2/4/03	Giad, et al.			
FOREIGN PATENT DOCUMENTS										
		Document Number				Date	Country	Class	Subclass	Translation
										Yes No
OTHER DOCUMENTS (Including Author, Title, Date, Pertinent Pages, Etc.)										
	47	Aharoni, et al., "Copolymer 1 induces T cells of the T helper type 2 that crossreact with myelin basic protein and suppress experimental autoimmune encephalomyelitis", <u>Proc. Natl. Acad. Sci. USA</u> , 1997, 94, 10821-10826								
	48	Aharoni, et al., "Cop 1 Specific Suppressor Cells Inhibit Experimental Allergic Encephalomyelitis Induced by Either Mouse Spinal Cord Homogenate or Proteolipid Protein Peptide 139-151", <u>Neurology</u> , 1997, Vol. 48, No. 3, A422								
	49	Aharoni, et al., "Bystander suppression of experimental autoimmune encephalomyelitis by T cell lines and clones of the Th2 type induced by copolymer 1", <u>Journal of Neuroimmunology</u> , 1998, 91, 135-146								
	50	Asakura et al., "A unique population of circulating autoantibodies promotes central nervous system remyelination", <u>Multiple Sclerosis</u> , 1998, 4, 217-221								
	51	Asakura et al., "Targeting of IgMk Antibodies to Oligodendrocytes Promotes CNS Remyelination", <u>The Journal of Neuroscience</u> , 1998, 18(19), 1700-1108								
	52	Batchelor, et al., <u>Lancet</u> , 1980 1(8178):1107-9								
	53	Bieber, et al., "Antibody-mediated remyelination: relevance to multiple sclerosis", <u>Multiple Sclerosis</u> , 2000, 6(2), S1-S5								
	54	Bieber, et al., "Humoral autoimmunity as a mediator of CNS repair", <u>A Trends Guide to Neurodegenerative Disease and Repair/Review</u> , 2001, 24(11), S39-S44								
	55	Bodanszky, M., "Principles of Peptide Synthesis," Springer-Verlag, Berlin, Heidelberg, New York, Tokyo, 1984, 118-229								
	56	Bornstein, "Clinical Experience: Hopeful Prospects In Multiple Sclerosis", <u>Hospital Practice</u> , 1992, Vol. 27, No. 5, pp. 135-158								
	57	Duda, et al., "Human and Murine CD4 T Cell Reactivity to a Complex Antigen: Recognition of the Synthetic Random Polypeptide Glatiramer Acetate", <u>The Journal of Immunology</u> , 2000, 165, 7300-7307								
EXAMINER						DATE CONSIDERED				
<p>*EXAMINER: Initial if citation considered, whether or not citation is in conformance with MPEP 609: Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.</p>										

Applicants: Rina Aharoni et al.
 Serial No.: 09/768,872
 Filed: January 23, 2001
Exhibit A

Applicants : Rina Aharoni et al.
 Serial No. : 09/768,872
 Filed : January 23, 2001

Exhibit B

Form PTO-1449		U.S. Department of Commerce Patent and Trademark Office		Atty. Docket No. 60772-PCT-US		U.S. Serial No. 09/768,872							
INFORMATION DISCLOSURE CITATION (Use several sheets if necessary)				Applicant: Rina Aharoni et al.		Group Art Unit							
				Filing Date: January 23, 2001									
U.S. PATENT DOCUMENTS													
Examiner Initial		Document Number						Date	Name	Class	Subclass	Filing Date if Appropriate	
	9	6	6	2	0	8	4	7	9/16/03	Konfino, et al.			
	10	6	8	0	0	2	8	5	10/5/04	Yong & Chabot			
	11	6	8	0	0	2	8	7	10/5/04	Gad, et al.			
	12	6	8	4	4	3	1	4	1/18/05	Eisenbach-Schwartz, et al.			
	13	6	9	3	9	5	3	9	9/6/05	Konfino et al.			
	14	7	0	2	2	6	6	3	4/4/06	Gilbert et al.			
FOREIGN PATENT DOCUMENTS													
		Document Number						Date	Country	Class	Subclass	Translation	
												Yes No	
OTHER DOCUMENTS (Including Author, Title, Date, Pertinent Pages, Etc.)													
	58	Fatma, et al., <u>Swiss Med. Wkly</u> , 2003, 133:541-543											
	59	Giuseppina, et al., <u>The Journal of Clinical Investigation</u> , April 2003, Vol. 111, No. 8, 1171-80											
	60	Harrison and Hafner, "Antigen-Specific Therapy for Autoimmune Disease", <u>Current Opin. Immunol.</u> , 2000, 12(6): 704-711											
	61	Johnson, et al. "Copolymer 1 reduces relapse rate and improves disability in relapsing-remitting multiple sclerosis: results of a phase III multicenter, double-blind placebo-controlled trial. The Copolymer 1 Multiple Sclerosis Study Group", <u>Neurology</u> , 45(7), 1268 (abstract)											
	62	Kobayashi, et al., <u>Clinical Exp. Immunology</u> , 1990, June 80(3):400-3											
	63	Korezyn, et al., "Safety profile Of copolymer 1: Analysis Of Cumulative Experience In The United States And Israel", <u>J. Neurol</u> , 1996, Vol. 243 (Suppl. 1), S23-S26											
	64	Lombardi, et al., <u>J. Invest. Dermatol.</u> , 1999 July 113(1):107-10											
	65	Lovell, K. and Jones, M., "CNS Infections, Spongiform Encephalopathy and Demyelinating Diseases," Karol Marcinkowski U. Med. Sci., Dept. Pathol., Poland, last updated on 2003-04-20, <URL:http://ampat.amu.edu.pl/guzyuno/CNS_INFE.HTM>											
	66	Lymberi, et al., <u>Arch. Hellen. Med.</u> , 16(4), July-August 1999, 337-351											
	67	McGavern, et al. "Do Antibodies Stimulate Myelin Repair in Multiple Sclerosis?", <u>The Neuroscientist</u> , 1999, 5(1), 19-28											
EXAMINER								DATE CONSIDERED					
<p>*EXAMINER: Initial if citation considered, whether or not citation is in conformance with MPEP 609: Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.</p>													

Form PTO-1449		U.S. Department of Commerce Patent and Trademark Office		Atty. Docket No. 60772-Z-PCCT-US		U.S. Serial No. 09/768,872							
INFORMATION DISCLOSURE CITATION (Use several sheets if necessary)				Applicant: Rina Aharoni et al.		Group Art Unit							
				Filing Date: January 23, 2001									
U.S. PATENT DOCUMENTS													
Examiner Initial		Document Number			Date	Name	Class	Subclass	Filing Date if Appropriate				
	15	7	0	3	3	5	8	2	4/25/06	Yong et al.			
	16	7	0	7	4	5	8	0	7/22/06	Gad et al.			
	17	20	02	00	37	8	4	8	3/28/02	Einsenbach-Schartz et al.			
	18	20	02	00	55	4	6	6	5/9/02	Aharoni et al.			
	19	20	02	00	77	2	7	8	6/20/02	Yong et al.			
	20	20	02	01	07	3	8	8	8/8/02	Vandenbark			
	21	20	03	01	70	7	2	9	9/11/03	Klinger			
	22	20	04	00	06	0	2	2	1/8/04	Strominger et al.			
FOREIGN PATENT DOCUMENTS													
		Document Number			Date	Country	Class	Subclass	Translation				
											Yes	No	
OTHER DOCUMENTS (Including Author, Title, Date, Pertinent Pages, Etc.)													
	68	Merck Manual of Diagnosis and Therapy, <u>Merck Research Laboratories</u> , Whitehouse Section, N.J., 17 th Ed., 1999, 1300-1303, 1312-1317											
	69	Pavelko, et al., "Acceleration in the Rate of CNS Remyelination in Lysolecithin-Induced Demyelination", <u>The Journal of Neuroscience</u> , 1998 18(7), 2498-2505											
	70	Pender, et al., <u>Internal Med. Journal</u> , 2002, 32: 554-563											
	71	<u>Pharmacia Biotech Directory</u> , 1996, pages 340-341											
	72	<u>Physician's Desk Reference</u> , 2000, Medical Economics Co. Inc., Montvale, NJ, 3115											
	73	Racadot, et al., "Treatment of Multiple Sclerosis With Anti-CD4 Monoclonal Antibody", <u>J. of Autoimmunity</u> , 1993, Vol. 6, pp. 771-786											
	74	Rodriguez, et al., "Immunoglobulins Reactive With Myelin Basic Protein Promote CNS Remyelination", <u>Neurology</u> , 1996, Vol. 46, pp. 538-545											
	75	Rodriguez, et al., " <u>Neurological Therapeutics</u> ", 1998, 15(3): 245-250											
	76	Sela, M., et al., "Synthetic Approaches to Vaccines for Infectious and Autoimmune Diseases", <u>Vaccine</u> , 1992, Vol. 10, Issue 14, 991-999											
	77	Sridama, et al., <u>Arch Intern Med.</u> , 1987, 147:229-231											
	78	Teva, et al., "Copolymer-I Glatiramer Acetate Copaxone Agent for Multiple Sclerosis", <u>Drugs of the Future</u> , 1998, Vol. 23, No. 2, 213-214											
	79	Ure, et al., "Polyreactive Antibodies To Glatiramer Acetate Promote Myelin Repair In Murine Model Of Demyelinating Diseas", <u>FASEB Journal</u> , 2002, Vol. 16, pp. 1260-1262											
EXAMINER						DATE CONSIDERED							
*EXAMINER: Initial if citation considered, whether or not citation is in conformance with MPEP 609: Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.													

Form PTO-1449		U.S. Department of Commerce Patent and Trademark Office		Atty. Docket No. 60772-Z-PCT-US		U.S. Serial No. 09/768,872							
INFORMATION DISCLOSURE CITATION (Use several sheets if necessary)				Applicant: Rina Aharoni et al.									
				Filing Date: January 23, 2001		Group Art Unit							
U.S. PATENT DOCUMENTS													
Examiner Initial		Document Number				Date	Name	Class	Subclass	Filing Date if Appropriate			
	23	20	05	00	19	3	2	2	1/27/05	Rodriguez et al.			
	24	20	05	01	70	0	0	4	8/4/05	Rosenberger			
	25	20	05	01	71	2	8	6	8/4/05	Konfino et al.			
	26	20	05	02	56	0	4	6	11/17/05	Gad et al.			
	27	20	06	00	52	5	8	6	3/9/06	Dolitzky			
	28	20	06	01	22	1	1	3	6/8/06	Pinchasi et al.			
	29	10	5	4	3	7	6	4	7/18/05	Aharoni et al.			
	30	10	5	4	7	4	6	3	8/30/05	Pinchasi et al.			
FOREIGN PATENT DOCUMENTS													
		Document Number				Date	Country	Class	Subclass	Translation			
											Yes	No	
OTHER DOCUMENTS (Including Author, Title, Date, Pertinent Pages, Etc.)													
	80	Vandenbark, et al., "Specificity Of T Lymphocyte Lines For Peptide Of Myelin Basic Protein", <u>The J. Of Immunology</u> , 1985, Vol. 135, pp. 229-233											
	81	Van Noort, et al., <u>International Review of Cytology</u> , 1996, 178: 127-205											
	82	Wan, et al., <u>Human Immunology</u> , 2002, Apr. 63(4):301-10											
	83	Warrington, et al., "Immunoglobulin-mediated CNS repair", <u>J. Allergy Clin. Immunol.</u> , 2001, S121-S125											
	84	Warrington, et al., "Human monoclonal antibodies reactive to oligodendrocytes promote remyelination in a model of multiple sclerosis", <u>Neurobiology</u> , 2000, 97(12), 6820-6825											
	85	Webster's II New Riverside University Dictionary, definition of "preventing", The Riverside Publishing Co., 1984, page 933											
	86	Weilbach, et al., "Disease Modifying Treatments For Multiple Sclerosis: What Is On The Horizon?" <u>CNS Drugs</u> , 1999, Vol. 11, No. 2, pp. 133-167											
	87	Wiesemann, et al., "Glatiramer Acetate (GA) induces IL-13/IL-5 secretion in naïve T cells", <u>Journal of Neuroimmunology</u> , 2001, 119, 137-144											
	88	Zhang, et al., "Murine Monoclonal Anti-Myelin Basic Protein (MBP) Antibodies Inhibit Proliferation And Cytotoxicity Of MBP-specific human T cell clones", <u>J. of Neuroimmunology</u> , 1989, Vol. 24, pp. 87-94											
	89	"About Copaxone", Internet Article URL: http://www.mswatch.com/therapy/section.aspx?SectionId=789eabf5-3a07-4dff-a7ee-0d4ad138a6d											
	90	URL: http://ntri.tamuk.edu/immunology/autoimmunity.html .											
EXAMINER							DATE CONSIDERED						
<p><small>*EXAMINER: Initial if citation considered, whether or not citation is in conformance with MPEP 609: Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.</small></p>													

